Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen

  • Michael Davies1
  • Yazan Samhouri2
  • Omid Hamid3
  • Giri Sulur4
  • Raina Duan5
  • Giridharan Ramsingh6
  • Allison Betof7
  • Alexander N Shoushtari8
  • Georgina V Long9
  • Gino K In10
  • Jason A Chesney11
  • Isabella C Glitza12
6 more authors
  • Hussein A Tawbi12
  • Rodabe N Amaria12
  • Tirrell T Johnson13
  • Jennifer L McQuade14
  • Parameswaran N Hari5
  • Ricky Rudraraju5
14 affiliations
  1. 1professor of building physics and the environment
  2. 2Medical Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
  3. 3The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, USA
  4. 46Iovance Biotherapeutics Inc., San Carlos, CA, USA
  5. 5Obsidian Therapeutics, Cambridge, MA, USA
  6. 62Obsidian Therapeutics, Cambridge, MA, USA
  7. 7Stanford University School of Medicine, Stanford, California, USA
  8. 8Memorial Sloan Kettering Cancer Center, New York City, NY, USA
  9. 9Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
  10. 10USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
  11. 11James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
  12. 12The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  13. 13Orlando Health Cancer Institute, Orlando, FL, USA
  14. 14JMQ Oncology Advisors LLC, Houston, TX, USA
Open at sourcePDFDOICite

Related

  1. Endoscopic Submucosal Dissection as a Diagnostic and Minimally Invasive Therapeutic Excision Modality for Primary Anorectal Malignant Melanoma
    Yusaku Yokotani, Hiroaki Kitae, Kyoka Ozawa +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textOncologyJ-STAGE
  2. Cost-Utility Analysis of First-Line Olaparib plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer in China after Volume-Based Procurement
    J. SHI, Q. Gu, J. Pan +2
    medRxivPreprintCC BYFull textEpidemiology & public healthmedRxiv
  3. 147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series
    Khola Khan, Daniel H Johnson
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. 330 Multi-omic analysis of TIL therapy in advanced checkpoint-refractory melanoma
    Elizabeth Park, Bita Sahaf, Amanda Kirane +13
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
    Anna Maria Di Giacomo, Matteo Simonelli, Agnese Losurdo +37
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full text3 citedGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{davies2026obx115,
  title = {{566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen}},
  author = {Michael Davies and Yazan Samhouri and Omid Hamid and Giri Sulur and Raina Duan and Giridharan Ramsingh and Allison Betof and Alexander N Shoushtari and Georgina V Long and Gino K In and Jason A Chesney and Isabella C Glitza and Hussein A Tawbi and Rodabe N Amaria and Tirrell T Johnson and Jennifer L McQuade and Parameswaran N Hari and Ricky Rudraraju},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0566},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0566},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 566 OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen
AU  - Michael Davies
AU  - Yazan Samhouri
AU  - Omid Hamid
AU  - Giri Sulur
AU  - Raina Duan
AU  - Giridharan Ramsingh
AU  - Allison Betof
AU  - Alexander N Shoushtari
AU  - Georgina V Long
AU  - Gino K In
AU  - Jason A Chesney
AU  - Isabella C Glitza
AU  - Hussein A Tawbi
AU  - Rodabe N Amaria
AU  - Tirrell T Johnson
AU  - Jennifer L McQuade
AU  - Parameswaran N Hari
AU  - Ricky Rudraraju
PY  - 2026
DA  - 2026/11/07
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0566
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0566
SN  - 2051-1426
ER  -